Hints and tips:
Related Special Reports
...BIA did not respond to requests for comment....
...Smith & Nephew wants to increase pay for its US executives to bring it closer to American levels, with Rupert Soames, the chair of the FTSE 100 medical devices company calling UK pay packages “not sustainable...
...Before most people knew what a camera was, the V&A was already amassing photographs....
...In 2019, Namal Nawana, an Australian who had worked in the US, quit as chief executive of Smith & Nephew because the UK medical devices company could not meet his pay demands....
...Morgan Stanley’s UK picks are mainly skewed towards bigger companies: BAE Systems, Ashtead, 3i, BP, Smith & Nephew, Haleon, Prudential, Rio Tinto, AstraZeneca, Invidior, Segro and SSE....
...(Sophia Smith) Listen in: How hybrid work affects women This week on the Working It podcast we spoke about hybrid work — is it a trap for women?...
...Those last allegations are almost certainly false, not least because the Duke of Clarence was in fact taking his nephews to a PizzaExpress at the time of the killings....
...Smith & Nephew has held talks to buy NuVasive, a maker of medical instruments used in spinal surgery, in a deal that would be worth more than $3bn and mark the largest acquisition by the British medical...
...Her appointment was, the private equity executive Robert Smith tweeted, both a great achievement and “a reminder of how much work is still ahead”....
...Smith & Nephew goes up to “overweight” at Morgan Stanley. A V-shaped recovery in kneecaps isn’t in the price, they say....
...Smith & Nephew “lowers growth outlook amid coronavirus uncertainty” and its shares are up more than 8 per cent....
...Investing in black founders and unconscious bias training can shake up an industry that has failed to act, writes Richard Robinson, chief executive of Robin AI....
...Of the large-cap health stocks, Vermeer Partners, another London-based wealth manager, favours medical device stocks Zimmer Biomet and Smith & Nephew, given that demand for elective surgery has been deferred...
...But in his 18-month stint at Smith & Nephew, Mr Nawana oversaw a 40 per cent increase in its share price....
...US outfits such as Cadwalader, Wickersham & Taft, Reed Smith, BCLP and Baker McKenzie have moved swiftly to cut both payouts for partners and salaries for more junior lawyers — going further than most UK...
...The FT View is that Mr Trump must drop political bias in allocating resources....
...What else we’re reading The People v Harvey Weinstein Only hours after Hollywood partied into the night, Harvey Weinstein hobbled up the steps to a New York City criminal court....
...FTSE 100 group Smith & Nephew had an even worse April than ITV. April revenues for the medical devices maker dropped 47 per cent, as elective surgeries have come to a halt in many countries....
...The lockdowns imposed to contain the virus are likely to have hit sales of drugs that need a doctor to administer them, while the delay in non-essential surgeries has hurt others including Smith & Nephew...
...application form) to want to give its market-leading savings account rates to arms dealers, gambling tycoons and crypto bros (a fact that was first picked up on by Alphaville friend and FT colleague Rob Smith...
...Mark Grant, chief global strategist at B Riley FBR Inc in Fort Lauderdale, Florida “My target for the S&P 500 by year end is 3,382 and the 10-year yield at 1.70 per cent . . ....
...Namal Nawana: competitive spirit UK medical devices maker Smith & Nephew seems keen to shift its listing to the US. That would give it a freer rein to raise the pay of chief exec Namal Nawana....
...Smith & Nephew states that ‘multiple [UK] private hospital groups [are] aiming for late June to restart’ – this is in line with our expectations given that the 14-week NHS deal started 30 March....
...Xerox wants to give HP’s board its walking papers We’re all guilty of overusing the David v Goliath trope but in the case of Xerox and HP, it really does apply....
...DD’s Indap v NYU’s Damodaran: Is stock compensation good or bad?...
International Edition